Regenxbio (NASDAQ: RGNX) reported Q2 EPS of ($0.04), $0.57 better than the analyst estimate of ($0.61). Revenue for the quarter ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE